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Letter to the editor 
Plasma membrane calcium ATPase 1 regulates human umbilical vein endothelial cell angiogenesis 
and viability 
Angiogenesis encompasses a series of regulated processes enabling 
endothelial tip cell migration, stalk cell proliferation and eventual vessel 
anastomosis and maturation. Recently, a role for plasma membrane 
calcium ATPase (PMCA), specifically PMCA4, in negatively regulating 
angiogenesis has been identified in vitro and in vivo. Knockdown of 
PMCA4 in human umbilical vein endothelial cells (HUVECs) leads to an 
increase in tubule formation and upregulation of regulator of Calci-
neurin 1 (RCAN1.4) signaling, a downstream effector of the calcineurin/ 
nuclear factor of T-cells (NFAT) pathway [1]. Furthermore, in vivo, 
functional suppression of PMCA4 leads to elevated reperfusion 
following induction of hindlimb ischaemia [1,2]. Given their function as 
Ca2+ extrusion pumps it is unsurprising that siRNA mediated knock-
down of either PMCA1 or PMCA4 in HUVECs results in increased [Ca2+]i 
[3–5] which has been shown to inversely correlate with endothelial 
sheet migration speed [3]. Recently, a mechanistic role for PMCA1 in 
endothelial nitric oxide synthase phosphorylation and insulin- 
dependent AKT activation has been described [4,5]. However, the im-
plications of PMCA1 knockdown on angiogenesis has yet to be 
determined. 
Knockdown of ATP2B1 (si-PMCA1), ATP2B4 (si-PMCA4), or non- 
targeting (si-NT) scrambled control (Dharmacon) in HUVECs (TCS 
Cellworks) was achieved using published methods [1,2]. To study 
wound migration, HUVECs were plated onto ImageLock 96-well plates 
(3 × 104 cells per well) and the scratch wound generated using the 
Incucyte ‘woundmaker’ (Sartorius). Images were captured and analysed 
using the Incucyte S3 Live Cell Analysis system and Zoom® analysis 
centre respectively. To determine tubule formation, HUVECs were 
plated onto Geltrex™ Low Growth Factor Matrix (Invitrogen, 3 × 104 
cells per well) in Medium 200 (0.2% FBS) containing either PBS or 25 
ng/ml VEGFa-165 (PeproTech). Following a 24-h incubation, wells were 
imaged using a Leica M165Fc stereomicroscope and LASX software 
(Leica). Tubules were quantified using Angiosys (version 2.0, TCS 
Cellworks). Western blot was performed on protein extracted from 
either basal or VEGFa-165-stimulated HUVECs using SDS-PAGE gel 
electrophoresis and Trans-Blot® Turbo™ (BioRad) protein transfer. 
Membranes were probed for the following: PMCA1, MCM7 (Santa- 
Cruz), MCM2, β-actin (Cell Signaling), MCM6 (ProteinTech), DSCR1 
(Sigma) and α-tubulin, Na+/K+ ATPase (Abcam). 
siRNA mediated ATP2B1 knockdown significantly reduces the pro-
tein expression of PMCA1 (Fig. 1A) and leads to an increase in intra-
cellular Ca2+ (data not shown). Transient PMCA1 knockdown results in 
decreased HUVEC viability over a period of days, altered cell cycle ki-
netics (Supplementary Fig. 1A and 1B) and significantly reduced 
expression of components of the key cell cycle mediator, the mini-
chromome complex (MCM, Fig. 1C). Interestingly, depletion of MCM 
occurs exclusively upon PMCA1, and not PMCA4, depletion 
(Supplementary Figs. 1D–1F). Furthermore, PMCA1 knockdown leads 
to impaired HUVEC migration; quantification of wound density and 
wound width revealed both are significantly reduced in si-PMCA1 
HUVECs (Fig. 1B). Impaired endothelial cell migration can impact on 
vessel formation and, when compared to VEGFa-165-stimulated si-NT 
controls, loss of PMCA1 results in a less complex in vitro vascular 
network, characterised by the formation of significantly fewer endo-
thelial junctions and tubules (Fig. 1D). Lastly, the protein expression of 
RCAN1.4 is also upregulated in response to VEGFa-165-stimulation which 
occurs to a significantly greater extent in si-PMCA1 HUVECs when 
compared to controls (Fig. 1D). 
Here we demonstrate that loss of PMCA1 impairs basal endothelial 
cell migration and VEGF-mediated tubule formation in vitro; and leads to 
a reduction in core components of the putative DNA helicase MCM. 
These characteristics are in contrast to recently published data which 
demonstrated that transient PMCA4 knockdown increases both HUVEC 
migration and VEGF-dependent tubule formation [1], suggesting that 
PMCA1 and PMCA4 may play opposing roles in angiogenesis. Interest-
ingly, both PMCA1 and PMCA4 knockdown models exhibit a VEGFa-165- 
dependent increase in RCAN1.4; however, in the context of PMCA1 
knockdown, upregulation of RCAN1.4 may further impair tubule for-
mation. Overexpression of RCAN1 supresses VEGF-mediated angiogen-
esis in vitro [6] and could therefore be inhibiting tubule formation in si- 
PMCA1 HUVECs. Furthermore, both PMCA1 and PMCA4 have been 
suggested to be putative regulators of VSMC growth and proliferation 
[7,8]. VSMCs isolated from PMCA4 knockout mice exhibit G1 cell cycle 
arrest [8], whereas it is an increase in PMCA1 in VSMC which causes a 
decrease in cell proliferation rate [7]. Conversely, in this study, it is a 
reduction in PMCA1 in HUVECs that reduces cell viability over time 
(Supplementary Fig. 1); interestingly, si-PMCA1 HUVECs exhibit a sig-
nificant downregulation in MCM complex components basally. The 
MCM complex functions as a putative DNA helicase during DNA syn-
thesis and its nuclear expression is tightly regulated to prevent re- 
replication [9]; however, MCM proteins exist in abundance and can 
function independently of their heterohexamer [10]. Furthermore, the 
expression of MCM2, MCM6 or MCM7 does not appear to be regulated 
by PMCA4 (Supplementary Fig. 1C–1F). 
Taken together, there is a clear distinction between the role of 
PMCA1 and PMCA4 in angiogenesis in vitro; PMCA4 is a negative 
regulator, whereas PMCA1 positively regulates endothelial cell angio-
genic phenotypes and viability. 
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Fig. 1. ATP2B1-silenced HUVECs show impaired wound migration, downregulated expression of minichromosome complex components 2, 6 and 7 and reduced 
tubule complexity. 
A) ATP2B1-targeting siRNA significantly depletes PMCA1 protein level (Students t-test, **p = 0.006, n = 3. B) IncuCyte real-time imaging of migrating HUVECs 
following generation of a scratch wound at Time 0- and 20-h post-scratch (scale bar = 300 μm). At Time20, wound density is significantly reduced and wound width 
significantly increased in si-PMCA1 HUVECs when compared to si-NT (Repeated measure two-way ANOVA with Sidak’s multiple comparison, wound density ***p =
0.0008, ****p < 0.0001 and wound width *p = 0.0361, ****p < 0.0001, n = 6 independent experiments, with a minimum of 3 technical repeats per experiment). C) 
Representative Western blot images and densitometric analysis showing reduced PMCA1 expression leads to a significant downregulation of components of the 
putative helicase minichromosome complex (Students t-test, MCM2 **p = 0.0026, MCM6 *p = 0.0178, MCM7 *p = 0.0259, n = 3). D) Representative images of in 
vitro tubule formation following PMCA1 knockdown (scale bar = 250 μm). Quantification of the number of junctions and tubules shows inhibition of endothelial cell 
morphogenesis in si-PMCA1 HUVECs when compared to si-NT HUVECs under VEGFa-165-stimulated conditions (# Students t-test, number of junctions ##p = 0.0035, 
number of tubules ##p = 0.0024 and *two-way ANOVA, number of junctions **p = 0.071, number of tubules **p = 0.0055, n = 7 independent repeats with a 
minimum of 3 technical repeats). Representative Western blot image and subsequent densitometric analysis shows VEGFa-165 is a potent activator of RCAN1.4 
expression in both groups; however, there is a significant increase in RCAN1.4 expression in si-PMCA1 when compared to non-targeting control levels HUVECS 
following VEGFa-165 –stimulation (two-way ANOVA, ***p = 0.0002, ****p < 0.0001, n = 3). All data shown are mean ± SEM, analysis performed using Graph-
Pad Prism. 
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Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.yjmcc.2021.03.011. 
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